To verified above assumption, we treated KC mice with erlotinib (an inhibitor of EGFR) for 1 month and found that erlotinib suppressed the formation of pancreatic precancerous lesions (Fig. 6a-c), reduced the loss of amylase+ acinar structures, the gain of CK19+ ductal structures and the expression of HSF1 target gene HSP70 (Fig. 6a and c). This evidence concerns the gene HSPA1A and keratoconus.